Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • cburke04
    Junior Member
    • Jan 2015
    • 2

    #1

    Breakpointer, Predicting Structural Variation from SE Illumina Reads + Reference

    Hello all,

    I am having some difficulty predicting were the breakpoints of a known large-scale inversion (~4-10 Mb, inferred by population genetics and QTL mapping) are using part of a reference genome and single-end 100 bp Illumina reads from a population sample. One complication is that the reference scaffold that I am using may not contain both inversion breakpoints as it is incomplete. My questions are:

    1) I am currently using the Breakpointer script from (https://github.com/ruping/Breakpointer), is there a better program to predict structural variants using single-end reads?

    2) Does anyone have experience with the output file for Breakpointer run with the script at (https://github.com/ruping/Breakpointer)? Are there particular portions of this output that would be most informative for IDing inversion breakpoints as I have 17,468 candidate regions (eg. less reads map to that particular location and the read is split?)? The first few lines of the output looks like this:

    chrscaffold935|size76515 Breakpointer Depth-Skewed 63195 63245 56.233 + . ID=chrscaffold935|size76515:63195;SIZE=51;DEPTH=29;EndsRatio=0.662;StartsRatio=1;BinomialScore=3.004;MIS=7;realMIS=2;MISRATE=0.364621;seedseq=AAAAGTGTTACCTTTAAACCCCCCT;MismatchScore=0.0161;SU=13;rank_SB=62.810;rank_SM=49.657
    chrscaffold348|size845032 Breakpointer Depth-Skewed 126749 126805 26.985 + . ID=chrscaffold348|size845032:126749;SIZE=57;DEPTH=24;EndsRatio=0.577;StartsRatio=0.448;BinomialScore=1.903;MIS=5;realMIS=1;MISRATE=0.361063;seedseq=TCAGTTGATGGACGAAACCAATTTA;MismatchScore=0.00158;SU=9;rank_SB=35.475;rank_SM=18.494
    chrscaffold600|size417131 Breakpointer Depth-Skewed 146682 146753 77.008 + . ID=chrscaffold600|size417131:146682;SIZE=72;DEPTH=117;EndsRatio=0.68;StartsRatio=0.235;BinomialScore=4.775;MIS=20;realMIS=0;MISRATE=0.251383;seedseq=CCACTTGATTTTAGCGATTCTGCGG;MismatchScore=0.097;SU=24;rank_SB=82.567;rank_SM=71.449
    chrscaffold641|size112415 Breakpointer Depth-Skewed 10518 10545 49.758 + . ID=chrscaffold641|size112415:10518;SIZE=28;DEPTH=6;EndsRatio=1;StartsRatio=0.238;BinomialScore=9.119;MIS=2;realMIS=0;MISRATE=0.333333;seedseq=TGTTGTGACGTGTTGTTTCCGCGGC;MismatchScore=2e-09;SU=1;rank_SB=99.474;rank_SM=0.041
    chrscaffold150|size493303 Breakpointer Depth-Skewed 179029 179104 60.675 + . ID=chrscaffold150|size493303:179029;SIZE=76;DEPTH=595;EndsRatio=0.499;StartsRatio=0.471;BinomialScore=1.611;MIS=90;realMIS=3;MISRATE=0.303127;seedseq=TTATTGCTAATTTAAATAAGGTTTT;MismatchScore=2.67;SU=1;rank_SB=22.620;rank_SM=98.729
    chrscaffold218|size453784 Breakpointer Depth-Skewed 285154 285184 26.029 + . ID=chrscaffold218|size453784:285154;SIZE=31;DEPTH=40;EndsRatio=0.475;StartsRatio=0.476;BinomialScore=1.146;MIS=3;realMIS=0;MISRATE=0.157895;seedseq=ACCTTTAAAACTGTTTTTCTCTTAA;MismatchScore=0.0158;SU=13;rank_SB=2.611;rank_SM=49.447
    chrscaffold35|size722381 Breakpointer Depth-Skewed 659136 659214 63.288 + . ID=chrscaffold35|size722381:659136;SIZE=79;DEPTH=26;EndsRatio=0.736;StartsRatio=0.195;BinomialScore=2.9;MIS=9;realMIS=0;MISRATE=0.470318;seedseq=TACCTATACATTTCCTAGGATATGT;MismatchScore=0.0567;SU=4;rank_SB=61.264;rank_SM=65.311
    chrscaffold621|size428421 Breakpointer Depth-Skewed 119257 119308 24.223 + . ID=chrscaffold621|size428421:119257;SIZE=52;DEPTH=34;EndsRatio=0.487;StartsRatio=0.546;BinomialScore=1.381;MIS=5;realMIS=1;MISRATE=0.301969;seedseq=ATCGAAAAAGCTAAGGCTAAAAACC;MismatchScore=0.00676;SU=5;rank_SB=11.607;rank_SM=36.838
    chrscaffold48|size965936 Breakpointer Depth-Skewed 18878 18964 22.985 + . ID=chrscaffold48|size965936:18878;SIZE=87;DEPTH=29;EndsRatio=0.662;StartsRatio=0.429;BinomialScore=2.195;MIS=4;realMIS=1;MISRATE=0.208355;seedseq=CAATTATTTTGTAAATGTTTACACG;MismatchScore=2e-09;SU=4;rank_SB=45.925;rank_SM=0.046
    chrscaffold621|size428421 Breakpointer Depth-Skewed 143393 143427 70.720 + . ID=chrscaffold621|size428421:143393;SIZE=35;DEPTH=20;EndsRatio=0.852;StartsRatio=0.908;BinomialScore=5.829;MIS=3;realMIS=1;MISRATE=0.176056;seedseq=AATTTAATACAGGTACGACTGTACC;MismatchScore=0.0177;SU=24;rank_SB=90.552;rank_SM=50.887
    chrscaffold348|size845032 Breakpointer Depth-Skewed 24245 24294 78.876 + . ID=chrscaffold348|size845032:24245;SIZE=50;DEPTH=29;EndsRatio=0.818;StartsRatio=0.466;BinomialScore=5.002;MIS=14;realMIS=3;MISRATE=0.590169;seedseq=TCTATATTTTGGTGCAGTCCTGTTG;MismatchScore=0.113;SU=1;rank_SB=84.565;rank_SM=73.187
    chrscaffold50|size611115 Breakpointer Depth-Skewed 570718 570765 46.314 + . ID=chrscaffold50|size611115:570718;SIZE=48;DEPTH=9;EndsRatio=0.739;StartsRatio=0.805;BinomialScore=3.418;MIS=3;realMIS=0;MISRATE=0.45106;seedseq=CCTAATCCTATGTCCTTCTCCTGGC;MismatchScore=0.00275;SU=5;rank_SB=68.357;rank_SM=24.271
    chrscaffold502|size248588 Breakpointer Depth-Skewed 100735 100761 54.273 + . ID=chrscaffold502|size248588:100735;SIZE=27;DEPTH=8;EndsRatio=0.785;StartsRatio=1;BinomialScore=3.581;MIS=3;realMIS=1;MISRATE=0.477707;seedseq=TGGTTCTAGGCCCTAAATCGTTAAT;MismatchScore=0.00748;SU=4;rank_SB=70.241;rank_SM=38.306
    chrscaffold546|size598492 Breakpointer Depth-Skewed 475284 475375 30.852 + . ID=chrscaffold546|size598492:475284;SIZE=92;DEPTH=44;EndsRatio=0.549;StartsRatio=0.414;BinomialScore=1.776;MIS=6;realMIS=1;MISRATE=0.248385;seedseq=AAACATGTTTACATTATTATGGTAC;MismatchScore=0.00474;SU=5;rank_SB=29.983;rank_SM=31.720
    chrscaffold15|size673834 Breakpointer Depth-Skewed 313308 313396 73.223 + . ID=chrscaffold15|size673834:313308;SIZE=89;DEPTH=112;EndsRatio=0.688;StartsRatio=0.275;BinomialScore=4.532;MIS=11;realMIS=2;MISRATE=0.142753;seedseq=GCCTTAATCCACGCGAATTCGATGG;MismatchScore=0.0603;SU=19;rank_SB=80.435;rank_SM=66.011
    chrscaffold621|size428421 Breakpointer Depth-Skewed 380187 380235 36.980 + . ID=chrscaffold621|size428421:380187;SIZE=49;DEPTH=64;EndsRatio=0.5;StartsRatio=0.574;BinomialScore=1.609;MIS=3;realMIS=0;MISRATE=0.09375;seedseq=AATGGTTTAATGCCCGTTTTCACCA;MismatchScore=0.0185;SU=3;rank_SB=22.510;rank_SM=51.450
    chrscaffold189|size410278 Breakpointer Depth-Skewed 264356 264391 83.797 + . ID=chrscaffold189|size410278:264356;SIZE=36;DEPTH=52;EndsRatio=0.666;StartsRatio=0.958;BinomialScore=3.636;MIS=22;realMIS=5;MISRATE=0.635251;seedseq=TGTAAGACTAGCGGCCGCCCGCGAC;MismatchScore=1.5;SU=14;rank_SB=70.978;rank_SM=96.616
    chrscaffold155|size350779 Breakpointer Depth-Skewed 191704 191757 11.213 + . ID=chrscaffold155|size350779:191704;SIZE=54;DEPTH=18;EndsRatio=0.533;StartsRatio=0.433;BinomialScore=1.285;MIS=2;realMIS=0;MISRATE=0.208464;seedseq=GCGTAAGTCCGTTGATTGGGATCAT;MismatchScore=0.00115;SU=3;rank_SB=7.363;rank_SM=15.064

    Any help would be greatly appreciated!

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    Yesterday, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 05:39 AM
0 responses
11 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-13-2026, 09:56 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-09-2026, 11:14 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-29-2026, 09:51 AM
0 responses
77 views
0 reactions
Last Post SEQadmin2  
Working...